Steven P. Damon

President and CEO

Steve Damon, founder of 4P Therapeutics, has over 20 years of experience with various business roles in the medical and pharmaceutical industries. Before founding 4P Therapeutics, Steve led the Business Development team at Altea Therapeutics as the company's Senior Vice President of Business Development. He was responsible for executing several key partnerships with various pharmaceutical companies for Altea's novel transdermal patch technology, bringing over $45 million of non-dilutive financing into Altea Therapeutics. Also, Steve currently serves on the board of directors for Georgia BIO.

Prior to joining Altea Therapeutics, Steven Damon was at Durect Corporation in Cupertino, Ca, where in addition to completing product partnership agreements, he was was responsible for other commercial activities including the Alzet brand drug delivery pumps and was President of a wholly owned subsidiary - Absorbable Polymers International. He was previously at Kimberly-Clark Healthcare, with lead responsibilities for commercial development of the healthcare business in Europe and key responsibilities for a number of major acquisition deals. 

 
 

Alan Smith, Ph.D.

Vice President, Clinical, Regulatory, Quality, & Operations

Alan Smith, Ph.D., co-founded 4P Therapeutics in 2011 and serves as Vice President, Clinical, Regulatory, Quality, and Operations. Previously, he was with Altea Therapeutics, most recently serving as Vice President, Product Development and Head of Clinical R&D, Regulatory Affairs, and Project Management. At Altea, he led major research and development programs with pharmaceutical companies such as Eli Lilly, Amylin, Hospira, Elan, and Novartis. He joined Altea as one of the first employees and spent 12 years growing its multidisciplinary drug delivery research and development organization.

Dr. Smith has 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical devices for treatment and management of diabetes, chronic pain and cardiovascular disease. Prior to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company. Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery.

 
 

David Enscore, Ph.D.

Principal Scientist

David J. Enscore advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies. Over the last several years, he has provided product development direction to the pharmaceutical and medical device industries on a consulting basis. His focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems. In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent.

He has served as an expert witness in several patent litigation cases involving transdermal technology. Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs. Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants.

Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation. At Alza, he lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber. He has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers. Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.

 
 

Jeffrey Gaulding, Ph.D.

Senior Research Scientist

Jeffrey Gaulding, Ph.D., joined 4P in 2013 and supports Research and Development activities in formulation and product development. Dr. Gaulding completed his doctorate in Chemistry from Georgia Tech in 2013, where he also received fellowships from the Georgia Tech Center for Drug Design, Development, and Delivery, the Technological Innovation: Generating Economic Returns program, as well as an NIH Training Grant on the development of Biomaterials.

Prior to his doctoral studies, Dr. Gaulding worked for GlaxoSmithKline in Research Triangle Park, North Carolina from 2006-2008, in a lab focused on optimizing physical properties for early stage drug compounds. Dr. Gaulding earned his BS in Chemistry from Emory University in 2006.

 
 

Pei-Ling Roerig, BS, CCRC

Director, Clinical Research

Pei-Ling Roerig is a well-rounded clinical research professional with over 15 years of experience in the design and conduct of drug and device clinical trials. She has experience operating successful Phase I - IV clinical trials from both an Investigator Site perspective as well as a Pharmaceutical/Biotech Sponsor standpoint.

From 2007 to 2011, Pei-Ling was the Phase I Clinical Trials Unit Manager at Altea Therapeutics, a developer of novel transdermal products. In addition, she has held Clinical Trials Manager positions at major hospital-based research centers including St. Joseph’s Translational Research Institute and Children’s Healthcare of Atlanta, and CardioMEMS – a medical device company and developer of an implantable wireless arterial pressure monitoring system. She received her undergraduate degree from the University of Central Florida.